Previous 10 | Next 10 |
Gainers: REVG +6.9% . MU +3.4% . PCG +2.2% . OBSV +2.8% . DERM +1.1% . More news on: REV Group, Inc., Micron Technology, Inc., PG&E Corporation, Stocks on the move, , News on ETFs Read more ...
A Phase 2b clinical trial evaluating Minerva Neurosciences' (NASDAQ: NERV ) MIN-117 in adults with moderate-to-severe major depressive disorder (MDD) failed to achieve the primary endpoint and key secondary endpoints. More news on: Minerva Neurosciences, Inc., Healthcare stocks news, S...
MIN-117 study did not meet its primary (MADRS) and key secondary (HAM-A) endpoints MIN-117 was generally well-tolerated with a safety profile comparable to placebo Company to host conference call at 5:00 p.m. today (dial-in information below) WALTHAM, Mass., Dec. 18, 2019 (GLOBE NE...
Biotech Pulse Biotechs finally have a gust of wind in their sails. In a space of 2 months, biotechs have gone from recording yearly lows in early October, to recording 2019 highs. The 25% surge has been a result of a relatively less threatening regulatory environment and a strengthening of...
SANTA CLARA, Calif., Dec. 04, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that Jeri Hilleman has joined its Board of Directors, effective imme...
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies ...
Minerva Neurosciences, Inc. (NERV) Q3 2019 Earnings Conference Call November 4, 2019 08:30 ET Company Participants William Boni - VP IR & Corporate Communications Remy Luthringer - Executive Chairman & CEO Geoff Race - EVP, CFO & Chief Business Officer Conference C...
Image source: The Motley Fool. Minerva Neurosciences Inc (NASDAQ: NERV) Q3 2019 Earnings Call Nov 4, 2019 , 8:30 a.m. ET Operator Continue reading
Minerva Neurosciences (NASDAQ: NERV ): Q3 GAAP EPS of -$0.36 in-line. More news on: Minerva Neurosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported key business updates and financial results for the...
News, Short Squeeze, Breakout and More Instantly...
Minerva Neurosciences Inc Company Name:
NERV Stock Symbol:
NASDAQ Market:
Minerva Neurosciences Inc Website:
BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first q...
A look at the top 10 most actives in the United States SoundHound AI Inc. (SOUN) rose 19.3% to $6.86 on volume of 301,330,136 shares Canoo Inc. (GOEV) rose 8.3% to $0.1138 on volume of 118,801,751 shares Ault Alliance Inc. (AULT) rose 19.1% to $0.4642 on volume of 117,184,555 shares Mar...